+179.4%
RCL vs GSK
+53.4%
+126.0%
-35.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.3% | -2.7% | +2.4% | +0.1% |
| 7D | -0.5% | -4.2% | +3.7% | +0.1% |
| 30D | -17.3% | -7.5% | -9.8% | -16.5% |
| 3M | -2.8% | -3.3% | +0.5% | -2.3% |
| 6M | -4.4% | -9.3% | +4.9% | -3.1% |
| YTD | -4.2% | +1.6% | -5.8% | -3.4% |
| 1Y | -23.4% | +25.5% | -48.9% | -22.8% |
| 3Y | +179.4% | +49.3% | +130.1% | +169.2% |
| All | +179.4% | +53.4% | +126.0% | +169.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling